A5033251316- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Asthma and respiratory diseases
- Autoimmune Bullous Skin Diseases
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Allergic Rhinitis and Sensitization
- Urticaria and Related Conditions
- Health and Medical Studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
- Retinoids in leukemia and cellular processes
- SARS-CoV-2 and COVID-19 Research
- Pregnancy and Medication Impact
- Complementary and Alternative Medicine Studies
- Monoclonal and Polyclonal Antibodies Research
- Oral Health Pathology and Treatment
- Tuberculosis Research and Epidemiology
- Immunodeficiency and Autoimmune Disorders
- Vitamin D Research Studies
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Cytokine Signaling Pathways and Interactions
- Rheumatoid Arthritis Research and Therapies
University Hospital Schleswig-Holstein
2014-2025
University of Lübeck
2014-2025
Clinical Research Center Kiel
2015-2024
University Medical Center
2016-2024
University Hospital and Clinics
2016-2024
Kiel University
2006-2024
Psoriasis Association
2016-2024
Universitäts Hautklinik Kiel
2012-2023
Schmerzklinik Kiel
2016-2023
John H. Stroger, Jr. Hospital of Cook County
2016
Recent studies have successfully demonstrated the use of deep-learning algorithms for dermatologist-level classification suspicious lesions by excessive proprietary image databases and limited numbers dermatologists. For first time, performance a algorithm trained open-source images exclusively is compared to large number dermatologists covering all levels within clinical hierarchy.We used methods from enhanced deep learning train convolutional neural network (CNN) with 12,378 dermoscopic...
In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk severe disease, for example, those receiving immunosuppressive therapies chronic inflammatory cdiseases (CIDs), are prioritised vaccination. However, data concerning generation protective antibody titres in immunosuppressed patients scarce. Additionally, mRNA vaccines represent new vaccine technology leading to increased insecurity especially with CID.Here we present first time, on...
Summary Background GP2015 is a proposed etanercept biosimilar. Objectives To demonstrate equivalent efficacy, and comparable safety immunogenicity of the originator (ETN, Enbrel®) in patients with moderate-to-severe chronic plaque-type psoriasis. Methods In total, 531 eligible were randomized 1 : to self-administer or ETN twice weekly subcutaneously. Patients ≥ 50% improvement Psoriasis Area Severity Index (PASI 50) at week 12 rerandomized continue same treatment on once-weekly dosing...
The use of monoclonal antibodies has changed the treatment several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally interleukin-23-receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.
Rare variants in the genes IL36RN, CARD14 and AP1S3 have been identified to cause or contribute pustular skin diseases, primarily generalized psoriasis (GPP).To better understand disease relevance of these genes, we screened our cohorts patients with diseases [primarily GPP palmoplantar (PPP)] for coding changes three genes. Carriers single heterozygous IL36RN mutations were a second mutation IL36RN.Coding exons sequenced 67 - 61 GPP, two acute exanthematous pustulosis four acrodermatitis...
BackgroundFew studies have analyzed the blood transcriptome in atopic dermatitis (AD).ObjectiveWe explored transcriptomic features of moderate to severe AD.MethodsBlood messenger RNA sequencing on 60 adults from TREATgermany registry including 49 patients before and after dupilumab treatment, as well an independent cohort 31 43 controls was performed. Patient clustering, differential expression, correlation coexpression network analysis, unsupervised learning were conducted.ResultsAD showed...
Abstract Background Interleukin (IL)-13 is a key driver of inflammation and barrier dysfunction in atopic dermatitis (AD). While there robust evidence that tralokinumab – monoclonal antibody neutralizes IL-13 reduces clinical disease activity, less known about its effects on function. Objectives To characterize the treatment skin Methods Transepidermal water loss (TEWL), stratum corneum hydration (SCH), natural moisturizing factor content, histopathological characteristics, biomarker...
Smoking and alcohol may contribute as triggering factors for psoriasis are substantial managing severely affected patients.To evaluate the general state of smoking intake in a group hospitalized, patients with comparison population Germany.A retrospective, multicentre study analysing data from 1,203 severe was performed.43.3% all were found to be active smokers (males: 46.6%; females: 39.2%) higher likelihood control (odds ratio, OR, 2.08, 95% confidence interval, CI, 1.81-2.39; p < 0.0001)....
Abstract: White adipose tissue is known to be involved in numerous physiological processes such as insulin‐mediated functions, lipid and glucose metabolism, vascular changes coagulation. These are mainly mediated by adipokines that secreted either from adipocytes or cells of the stromal‐vascular fraction tissue. In obesity, a shift production can mediate development associated diseases, metabolic syndrome, complications, artherosclerosis, myocardial infarction stroke, which comorbidities...
Abstract Background EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque‐type psoriasis as part of totality evidence gathered during the development GP 2015, an etanercept biosimilar. Objective To demonstrate equivalent comparable immunogenicity 2015 originator product ( ETN , Enbrel ® ) evaluate effects repeated switching between . Results for efficacy, treatment period TP 2 2) are presented pooling two continued arms (pooled continued) versus...
Abstract Background Psoriasis is associated with metabolic, liver and cardiovascular comorbidity. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, has shown significant sustained efficacy in the treatment of moderate to severe psoriasis. Objectives This was an exploratory post hoc analysis pooled data from three phase 3 studies plaque psoriasis patient populations. The objective show course metabolic parameters under secukinumab, etanercept or...
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening inflammatory skin disease. Our aim was to assess patient and disease characteristics analyze drug survival rates in the treatment of GPP real-life setting. In this retrospective study, 201 series 86 patients with treated at five University Medical Centers were analyzed. Overall, excellent response reached 41.3% all courses, partial 31.4%, nonresponse 27.3%. Biological significantly more effective than non-biological...
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our objective was to evaluate the long-term efficacy and safety ixekizumab in psoriasis through 5 years. Data were integrated from UNCOVER-1 UNCOVER-2, randomized, double-blinded, phase-3 trials. Patients who continuously received labeled dose, static Physician's Global Assessment (sPGA) (0,1) responders at Week 12 completed 60 weeks...
Abstract Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to not fully explained variation at robustly risk loci. To move towards saturation map susceptibility we meta-analysed 18 GWAS comprising 36,466 cases and 458,078 controls 109 distinct loci, 45 that been previously reported. These include variants loci in which...
Recently, it has been questioned whether vaccination of patients with inflammatory (auto)immune diseases under anti-tumor necrosis factor (TNF) treatment leads to impaired vaccine-induced immune responses and protection against breakthrough infections. However, the effects TNF blockade on short- long-term after repeated remain unclear. Vaccination studies have shown that initial short-term IgG antibodies (Abs) carry highly galactosylated sialylated Fc glycans, whilst Abs low levels...